Member Posts > How Cardiol Therapeutics' CRD-38 is Changing the Landscape of Heart Failure Treatment
Heart failure (HF) is a multifactorial condition, with mitochondrial dysfunction playing a pivotal role in disease progression. When mitochondria fail, ATP production declines, oxidative stress levels rise, and cardiomyocytes experience damage, leading to worsening heart function. Cardiol Therapeutics' CRD-38 is an innovative therapy aimed at directly addressing these mitochondrial deficiencies. By utilizing cannabidiol (CBD), CRD-38 reduces oxidative stress, alleviates inflammation, and preserves mitochondrial function. Moreover, it activates PPAR-γ, which promotes mitochondrial biogenesis and enhances energy production in heart cells. Preclinical studies indicate that CRD-38 improves mitochondrial respiration, reduces oxidative damage, and enhances overall cardiac output. This makes it particularly promising for patients with HFpEF, who suffer from metabolic inefficiencies. Cardiol Therapeutics is currently advancing CRD-38 through the regulatory process to bring this potentially groundbreaking treatment into clinical trials.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38